文献速递特殊人群用药

基于电子健康记录与残余标本的儿童右美托咪定群体药代动力学分析

Population pharmacokinetic analysis of dexmedetomidine in children using real-world data from electronic health records and remnant specimens.
PubMed 文献 · Br J Clin Pharmacol · 2022-01-28

AIMS: Our objectives were to perform a population pharmacokinetic analysis of dexmedetomidine in children using remnant specimens and electronic health records (EHRs) and explore the impact of patient's characteristics and pharmacogenetics on dexmedetomidine clearance.…

要点

  • 体重和年龄是右美托咪定清除率的重要预测因素。
  • 基因型(UGT1A4、UGT2B10、CYP2A6风险评分)无显著临床影响。
  • 可利用电子健康记录和残余标本进行儿童群体药代动力学研究。

核心结论

  • 体重和年龄是右美托咪定清除率的重要预测因素。
  • 未发现UGT1A4或UGT2B10基因型或CYP2A6风险评分的药物遗传学效应。

研究设计与样本

  • 研究纳入354例0-22岁(中位16月)心脏术后患者,利用电子健康记录和残余标本进行群体药代动力学分析。
  • 采用非线性混合效应模型,分两阶段:第一阶段不含基因变量,第二阶段加入药物遗传学效应。

主要发现

  • 最终模型为二室模型,体重采用异速增长缩放,年龄采用Hill成熟函数。
  • 总清除率为27.3 L/h(95%CI 24.0-31.1 L/h),中央室分布容积为161 L(95%CI 139-187 L)。
  • 达到50%成人清除率的经后年龄估计为42.0周(95%CI 41.5-42.5周),Hill系数为7.04(95%CI 6.99-7.08)。

临床怎么用

  • 临床可依据体重和年龄预测右美托咪定清除率,调整儿童用药剂量。
  • 基因型检测(UGT1A4、UGT2B10、CYP2A6)对剂量调整无显著指导意义。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Our objectives were to perform a population pharmacokinetic analysis of dexmedetomidine in children using remnant specimens and electronic health records (EHRs) and explore the impact of patient's characteristics and pharmacogenetics on dexmedetomidine clearance. METHODS: Dexmedetomidine dosing and patient data were gathered from EHRs and combined with opportunistically sampled remnant specimens. Population pharmacokinetic models were developed using nonlinear mixed-effects modelling. Stage 1 developed a model without genotype variables; Stage 2 added pharmacogenetic effects. RESULTS: Our final study population included 354 post-cardiac surgery patients aged 0-22 years (median 16 mo). The data were best described with a 2-compartment model with allometric scaling for weight and Hill maturation function for age. Population parameter estimates and 95% confidence intervals were 27.3 L/h (24.0-31.1 L/h) for total clearance, 161 L (139-187 L) for central compartment volume of distribution, 26.0 L/h (22.5-30.0 L/h) for intercompartmental clearance and 7903 L (5617-11 119 L) for peripheral compartment volume of distribution. The estimate for postmenstrual age when 50% of adult clearance is achieved was 42.0 weeks (41.5-42.5 weeks) and the Hill coefficient estimate was 7.04 (6.99-7.08). Genotype was not statistically or clinically significant. CONCLUSION: Our study demonstrates the use of real-world EHR data and remnant specimens to perform a population pharmacokinetic analysis and investigate covariate effects in a large paediatric population. Weight and age were important predictors of clearance. We did not find evidence for pharmacogenetic effects of UGT1A4 or UGT2B10 genotype or CYP2A6 risk score.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. James NT, Breeyear JH, Caprioli R, et al. Population pharmacokinetic analysis of dexmedetomidine in children using real-world data from electronic health records and remnant specimens. Br J Clin Pharmacol. 2022. PMID: 34957589. doi:10.1111/bcp.15194

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。